And Boston Scientific hasn’t even asked for a bailout from Congress.
The dubiousness ranking is compiled by Forbes using metrics based on total compensation for the current fiscal year (salary, bonuses, stock options, etc.) and an efficiency ranking based on company’s performance during a six-year period, according to the magazine. Tobin’s efficiency ranking was 176, only three notches below the lowest score the magazine doled out.
According to Forbes‘ calculations, Boston Scientific posted an overall return of -14 percent over the last six years and a total return of -7 percent during Tobin’s tenure. Even so, Tobin took home $8.6 million in total compensation last year, slightly less than the $9 million he earned in 2007.
And, as MassDevice reported last month, he also received a generous 2008 stock grant of 2 million shares — valued at around $16 million.